Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in need for hospitalisation compared with antiplatelet agent (low certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).
1 finding from 1 review
Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
Anticoagulant with or without ASA showed no clear difference in thrombosis Median compared with ASA only (low certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
5 participants
GRADE not reported
Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review
Bleeding ‐ other (bleeding during first trimester) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ other (bleeding during first trimester) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review
Bleeding ‐ other (postpartum haemorrhage) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ other (postpartum haemorrhage) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
GRADE not reported
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Bleeding ‐ major/excessive · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Subcutaneous bruises · people with antiphospholipid antibodies and no history of thrombosis
ASA + high‐dose LMWH showed no clear difference in subcutaneous bruises compared with ASA + low‐dose LMWH or UFH (low certainty).
1 finding from 1 review